

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

COMPLETION OF THE H SHARE FULL CONVERSION

References are made to the announcements of Shandong Weigao Group Medical Polymer Company Limited* (the “**Company**”) dated 10 July 2018 and 2 August 2018 in relation to the participation in the H share full circulation pilot project by the Company to convert and list up to 2,638,600,000 unlisted or domestic shares into H Shares (the “**Conversion**”). Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the announcement dated 10 July 2018.

COMPLETION OF THE H SHARE FULL CONVERSION

The Board is pleased to announce that the Conversion was completed on 7 August 2018.

On 2 August 2018, the Company obtained the approval for the listing of and for permission to trade 2,638,600,000 H shares (“**Converted H Shares**”), being the maximum unlisted or domestic shares to be converted under the Conversion). Share certificates for the Converted H Shares were despatched to the relevant Shareholders on 7 August 2018 and the listing of the Converted H Shares will commence at 9:00 a.m. on 8 August 2018. The domestic participating shareholders of the Company can only conduct share trading subject to the completion of the domestic arrangement procedures as stated in the announcement dated 2 August 2018.

* *For identification purpose only*

SHARE CAPITAL STRUCTURE

The share capital structure of the Company before and after the Completion of the Conversion is as follows:

Class of shares	Before Completion of the Conversion		After Completion of the Conversion	
	Number of shares	Percentage (approximately)	Number of shares	Percentage (approximately)
Unlisted or domestic shares	2,638,600,000	58.3%	0	0
H shares	1,883,732,324	41.7%	4,522,332,324	100%
	<u>4,522,332,324</u>	<u>100.0%</u>	<u>4,522,332,324</u>	<u>100%</u>

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Hua Wei
Director

Weihai, 7 August 2018

As at the date hereof, the Board comprises of:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)